First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Byondis B.V.
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Part 1 (dose escalation): B-cell NHL expressing CD20 by immunohistochemistry (IHC) or flow cytometry, relapsed/refractory (R/R) to at least 2 prior lines of therapy or autologous CAR-T cell therapy.

• Part 2 (dose expansion):

A. Histologically confirmed diffuse large B-cell lymphoma (DLBCL) expressing CD20 by IHC or flow cytometry, R/R to frontline therapy; or R/R to second line salvage regimens or autologous hematopoietic cell transplantation or autologous CAR-T cell therapy.

B. Histologically confirmed marginal zone or follicular lymphoma (Grade 1-3a) expressing CD20 by IHC or flow cytometry, R/R to at least 2 prior lines of therapy or autologous CAR-T cell therapy.

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;

• Adequate organ function

Exclusion Criteria:

• Having been treated with CD47 or SIRPα targeting agents at any time or other anticancer therapy within 4 weeks or as defined in the protocol

• History of hypersensitivity or allergic reaction to any of the excipients of BYON4228 or rituximab which led to permanent discontinuation of the treatment;

• Burkitt's lymphoma;

• Red blood cell (RBC) transfusion dependence

• Patients with active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD;

• History of autoimmune hemolytic anemia or autoimmune thrombocytopenia;

• History of active autoimmune disorders (including but not limited to: Crohn's disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Grave's disease) or other conditions that compromise or impair the immune system (except for hypogammaglobulinemia);

• History (within 6 months prior to start IMP) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication;

• Symptomatic brain metastases, brain metastases requiring steroids or treatment for brain metastases within 8 weeks

• Severe active infection or other severe uncontrolled systemic disease (e.g. advanced renal disease, pulmonary, uncontrolled diabetes mellitus, severely immunocompromised state, or metabolic disease)